Ecnoglutide
vs Semaglutide.
Compare ecnoglutide and semaglutide using the direct SLIMMER-UP-SWITCH interim trial, China and FDA approvals, mechanism, results, and evidence limits.
What is the difference?
Ecnoglutide and semaglutide are GLP-1 receptor agonists with different product and regulatory records. A direct randomized open-label Phase 2 study in 163 Chinese adults with obesity reported mean weight changes of 12.8% with ecnoglutide and 9.5% with semaglutide at week 20, with both groups using 2.4 mg maintenance doses. That is direct interim evidence for one protocol, not a universal winner claim. Ecnoglutide is approved in China for chronic weight management and type 2 diabetes but is not FDA approved. WEGOVY is an FDA-approved semaglutide product with its own label, forms, indications, and safety record.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Ecnoglutide
Approved in China for type 2 diabetes and chronic weight management; not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 15 matched NCT records
- Sponsor
- Sciwind Biosciences; Pfizer commercialization partner in Mainland China
Semaglutide
FDA-approved prescription drug
- Route
- Subcutaneous and oral
- Registry
- Dedicated medicine evidence record
- Sponsor
- Novo Nordisk Inc.
Ecnoglutide vs Semaglutide: how direct is the evidence?
Ecnoglutide and Semaglutide were randomized within SLIMMER-UP-SWITCH. That provides direct group-level evidence for the exact population, doses, duration, endpoints, and analysis reported by the cited study. It does not create a universal winner outside that protocol.
Ecnoglutide
cAMP-signalling-biased GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- China approvals active; indication-expansion studies continue
- Status
- Approved in China for type 2 diabetes and chronic weight management; not FDA approved
One protocol, two randomized intervention groups.
Compare the randomized groups inside the cited protocol, then preserve its population, duration, dose, estimand, and reporting limits.
SLIMMER-UP-SWITCHSemaglutide
GLP-1 receptor agonist
- Route
- Subcutaneous and oral
- Stage
- NDA 215256 approved product record
- Status
- FDA-approved prescription drug
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 3
- Results posted
- 0
- Recruiting site observations
- 3
Outside this 13-program snapshot
This comparison uses an approved-medicine record here. A blank is a scope boundary, not evidence that no clinical trial or trial history exists.
Open the bounded clinical trial finder →Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Compare the randomized groups inside the cited protocol, then preserve its population, duration, dose, estimand, and reporting limits.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Ecnoglutide
cAMP-signalling-biased GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- China approvals active; indication-expansion studies continue
- Status
- Approved in China for type 2 diabetes and chronic weight management; not FDA approved
- Featured trial anchors
- NCT05813795 · NCT05680155 · NCT05680129
Semaglutide
GLP-1 receptor agonist
- Route
- Subcutaneous and oral
- Stage
- NDA 215256 approved product record
- Status
- FDA-approved prescription drug
- Featured trial anchors
- NDA 215256
Compare the field, then read the limit.
Unlike most pipeline comparisons, this pair has randomized direct evidence. The useful question is therefore not whether the percentages came from separate trials, but exactly what this head-to-head study tested. It enrolled a defined Chinese population, used open-label treatment, matched 2.4 mg maintenance doses, planned 60 weeks, and reported a prespecified week-20 interim analysis. Those boundaries matter before extending the result to every semaglutide product, dose, population, indication, or longer duration.
| Field | Ecnoglutide | Semaglutide | How to interpret it |
|---|---|---|---|
| Molecule design | cAMP-signalling-biased GLP-1 receptor agonist | GLP-1 receptor agonist with established product-specific FDA labels | Both engage GLP-1 receptors, but signalling design and product history differ and do not replace clinical outcomes or label-specific review. |
| Direct study | SLIMMER-UP-SWITCH ecnoglutide 2.4 mg maintenance group | SLIMMER-UP-SWITCH semaglutide 2.4 mg maintenance group | Randomization within one protocol makes this more informative than comparing unrelated headline percentages, while open-label interim reporting still limits certainty. |
| Week-20 mean change | 12.8% in the sponsor-reported interim analysis | 9.5% in the sponsor-reported interim analysis | These are protocol-specific interim group means, not an individual forecast or a comparison with every approved semaglutide regimen. |
| Current authorization | Approved in China for chronic weight management and type 2 diabetes; not FDA approved | WEGOVY is FDA approved for defined uses under NDA 215256 | Approval belongs to exact jurisdictions, products, presentations, and indications, so neither record transfers to an unrelated seller or formulation. |
| Evidence still needed | Final 60-week comparative efficacy and safety record | Final 60-week comparative efficacy and safety record within the same study | Longer follow-up, discontinuations, adverse events, missing data, and peer-reviewed publication remain essential to the final comparative reading. |
Why the headline numbers do not name a winner.
Sciwind's June 2026 report describes week-20 interim results from the planned 60-week SLIMMER-UP-SWITCH trial: 12.8% mean change with ecnoglutide and 9.5% with semaglutide, with at least 10% loss in 74% and 40% of participants, respectively. The study is randomized and direct, but open-label, sponsor-reported, limited to 163 Chinese adults with BMI of at least 30, and not yet accompanied here by final 60-week peer-reviewed results. The relative 35% headline is not a blanket comparison with every WEGOVY presentation or use.
Keep the comparison honest.
- 01
Describe the 12.8% and 9.5% results as a prespecified week-20 interim analysis from one open-label randomized Chinese Phase 2 study.
- 02
Keep ecnoglutide's China approvals separate from WEGOVY's FDA application, and do not transfer either approval to another product or jurisdiction.
- 03
Do not turn a 35% relative difference headline into a universal claim across all semaglutide brands, routes, doses, indications, populations, or durations.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →